Myriad Genetics Inc. (MYGN)

24.20
0.04 0.17
NASDAQ : Health Technology
Prev Close 24.24
Open 24.52
Day Low/High 24.05 / 24.91
52 Wk Low/High 20.10 / 48.40
Volume 762.34K
Avg Volume 1.39M
Exchange NASDAQ
Shares Outstanding 74.39M
Market Cap 1.76B
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

New Studies Demonstrate The Predictive Value Of The Vectra® Test In People Diagnosed With Rheumatoid Arthritis

New Studies Demonstrate The Predictive Value Of The Vectra® Test In People Diagnosed With Rheumatoid Arthritis

Vectra Test Predicts Radiographic Progression and CV Risks Associated with Inflammation

Myriad Genetics To Present At The 2019 Stephens Nashville Investment Conference

Myriad Genetics To Present At The 2019 Stephens Nashville Investment Conference

SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

GeneSight® Psychotropic Test Improved Clinical Outcomes For People With Depression Who Were Taking Medications With Gene-Drug Interactions

GeneSight® Psychotropic Test Improved Clinical Outcomes For People With Depression Who Were Taking Medications With Gene-Drug Interactions

New Analysis of GUIDED Trial Shows GeneSight Test Results Led to Statistically Significant Improvements in Remission, Response and Symptoms

Myriad Genetics Plummets as Earnings Trail Forecasts, Guidance Is Slashed

Myriad Genetics Plummets as Earnings Trail Forecasts, Guidance Is Slashed

Quarterly earnings greatly trail analysts' forecasts and Myriad Genetics sharply reduces guidance for fiscal 2020.

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

Myriad Genetics Reports Fiscal First-Quarter 2020 Financial Results

Total First-Quarter Revenues of $186.3 Million Excluding Out-of-Period Adjustments Revenue Would Have Been $197.

Myriad Genetics Announces Multiple Presentations At The 2019 American College Of Rheumatology Annual Meeting

Myriad Genetics Announces Multiple Presentations At The 2019 American College Of Rheumatology Annual Meeting

SALT LAKE CITY, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

Myriad To Announce Fiscal First-Quarter 2020 Financial Results On November 4, 2019

Myriad To Announce Fiscal First-Quarter 2020 Financial Results On November 4, 2019

SALT LAKE CITY, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

MYGN Investors: Reminder About November 26, 2019 Filing Deadline In Class Action - Contact Lieff Cabraser

MYGN Investors: Reminder About November 26, 2019 Filing Deadline In Class Action - Contact Lieff Cabraser

The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased or otherwise acquired the securities...

Myriad Genetics To Present Seven Studies At The 2019 National Society Of Genetic Counselors Annual Meeting

Myriad Genetics To Present Seven Studies At The 2019 National Society Of Genetic Counselors Annual Meeting

SALT LAKE CITY, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

FDA Approves Myriad's MyChoice® CDx Test To Help Identify Women Eligible For Treatment With Zejula® In Late-line Ovarian Cancer

FDA Approves Myriad's MyChoice® CDx Test To Help Identify Women Eligible For Treatment With Zejula® In Late-line Ovarian Cancer

First FDA Approval Advances Precision Medicine for Women with Ovarian Cancer Who have Received Three or More Previous Chemotherapy Regimens

Dr. Mark H. Pollack Named Chief Medical Officer For Myriad Neuroscience

Dr. Mark H. Pollack Named Chief Medical Officer For Myriad Neuroscience

Highly Accomplished Psychiatrist to Lead Company Efforts to Make GeneSight® Psychotropic Standard-of-Care in Clinical Practice

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Myriad Genetics, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc.

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Myriad Genetics, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Myriad Genetics, Inc.

Myriad Genetics Investors: Filing Deadline In MYGN Class Action - Contact Lieff Cabraser

Myriad Genetics Investors: Filing Deadline In MYGN Class Action - Contact Lieff Cabraser

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Myriad Genetics, Inc.

Myriad Genetics To Present Five Studies At The 2019 American Society Of Human Genetics Annual Meeting

Myriad Genetics To Present Five Studies At The 2019 American Society Of Human Genetics Annual Meeting

SALT LAKE CITY, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

ROSEN, A LEADING LAW FIRM, Reminds Myriad Genetics, Inc. Investors Of Important Deadline In Securities Class Action - MYGN

ROSEN, A LEADING LAW FIRM, Reminds Myriad Genetics, Inc. Investors Of Important Deadline In Securities Class Action - MYGN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces That A Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. And Encourages Investors To Contact The Firm

INVESTOR ALERT: Kirby McInerney LLP Announces That A Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. And Encourages Investors To Contact The Firm

The law firm of Kirby McInerney LLP is announcing that a class action lawsuit has been filed in the U.

MYGN CLASS ACTION DEADLINE: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Myriad Genetics

MYGN CLASS ACTION DEADLINE: Bernstein Liebhard LLP Announces The Filing Of A Securities Class Action Against Myriad Genetics

NEW YORK, Oct. 1, 2019 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of shareholders of Myriad Genetics ("Myriad" or the "Company")...

MYGN Loss Alert: Hagens Berman Notifies Investors In Myriad Genetics (MYGN) Of Securities Fraud Lawsuit

MYGN Loss Alert: Hagens Berman Notifies Investors In Myriad Genetics (MYGN) Of Securities Fraud Lawsuit

Class-action law firm urges MYGN investors who have suffered losses of 50K+ to learn their shareholder rights

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MYGN

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MYGN

NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Myriad Genetics, Inc.

MYGN LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

MYGN LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Myriad Genetics, Inc.

Myriad Genetics Expands Board Of Directors With Two Additional Members

Myriad Genetics Expands Board Of Directors With Two Additional Members

Colleen F. Reitan and Lee N. Newcomer, M.D., Elected to Myriad's Board of Directors

Myriad Announces Research Collaboration With University Of Leeds

Myriad Announces Research Collaboration With University Of Leeds

Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer

Prolaris® Test Identifies Men With Prostate Cancer Who Can Safely Defer Treatment

Prolaris® Test Identifies Men With Prostate Cancer Who Can Safely Defer Treatment

65 Percent of Patients Remained on Active Surveillance for More than Four Years

Myriad Genetics To Present At The 2019 Morgan Stanley Global Healthcare Conference

Myriad Genetics To Present At The 2019 Morgan Stanley Global Healthcare Conference

SALT LAKE CITY, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Myriad Genetics, Inc.

The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc.

TheStreet Quant Rating: C (Hold)